drugset / Trial / NCT05275439
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Non-randomizedSequentialOpen-labelTreatment
Summary
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Timeline
- Start
- 2022-03-17
- Primary completion
- 2025-02-06
- Completion
- 2025-02-06
Outcome
Missed primary endpoint
Stopped: “Development discontinued”
release “did not translate to clinically meaningful improvements in median overall survival for TP53m AML and HR-MDS patients” shattucklabs.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | SL-172154 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | SL-172154 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |